Neil Iyengar, Co-Director of Breast Oncology and Director of Cancer Survivorship at Emory University’s Winship Cancer Institute, shared a post on LinkedIn:
“Here we report initial/preliminary observations on GLP1 receptor agonist use in breast cancer survivors. This medical weight loss therapy prevented weight gain and induced modest (4-6%) weight loss, particularly during hormone therapy.
Weight gain is a major problem during adjuvant treatment for breast cancer. While we have seen larger magnitudes of weight loss with some types of lifestyle (diet/exercise) interventions, having another tool for weight loss is helpful.
We need (and are designing) clinical trials to determine the optimal dosing, scheduling, and use of medical weight loss therapy in cancer survivors (partially obesity-related cancers), and how best to integrate medical weight loss with lifestyle interventions.”
Title: GLP-1 Receptor Agonist Use and Weight Change in Patients With Breast Cancer
Authors: Sherry Shen, Bethina Liu
Read The Full Article at Cancer Network.
More posts featuring Neil Iyengar on OncoDaily.